Last 23.90 NOK
Change Today 0.00 / 0.00%
Volume 0.0
PCIB On Other Exchanges
Symbol
Exchange
Berlin
As of 10:25 AM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

pci biotech holding asa (PCIB) Snapshot

Open
21.50 NOK
Previous Close
23.90 NOK
Day High
23.90 NOK
Day Low
19.50 NOK
52 Week High
02/11/14 - 40.00 NOK
52 Week Low
11/18/13 - 16.00 NOK
Market Cap
184.7M
Average Volume 10 Days
1.9K
EPS TTM
-4.25 NOK
Shares Outstanding
7.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PCI BIOTECH HOLDING ASA (PCIB)

Related News

No related news articles were found.

pci biotech holding asa (PCIB) Related Businessweek News

No Related Businessweek News Found

pci biotech holding asa (PCIB) Details

PCI Biotech Holding ASA, a cancer focused biopharmaceutical company, engages in developing therapeutic products based on its proprietary photochemical internalisation (PCI) technology. The PCI technology induces triggered endosomal release and may be used to unlock the therapeutic potential of various modalities, such as small molecules, ADCs, and siRNA. Its programs in clinical development include photosensitizer Amphinex recurrent for the treatment of head and neck cancer (phase II) and bile duct cancer (phase I/II). The company is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination. PCI Biotech Holding ASA was founded in 2000 and is based in Lysaker, Norway.

Founded in 2000

pci biotech holding asa (PCIB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

pci biotech holding asa (PCIB) Key Developments

PCI Biotech Holding ASA Reports Consolidated Earnings Results for the Second Quarter and First Half Ended June 30, 2014

PCI Biotech Holding ASA reported consolidated earnings results for the second quarter and first half ended June 30, 2014. For the quarter, operating loss was NOK 8,383,000 compared with NOK 5,890,000 for the same period in the last year. Ordinary loss before taxes was NOK 8,131,000 compared to NOK 5,412,000 a year ago. Net loss was NOK 8,131,000 against NOK 5,412,000 for the same period in the last year. Net cash used in operations was NOK 9,245,000 against NOK 6,735,000 a year ago. Basic and diluted loss per share was NOK 1.05 against NOK 0.71 for the same period in the last year. For the first half, operating loss was NOK 17,791,000 compared with NOK 13,134,000 for the same period in the last year. Ordinary loss before taxes was NOK 17,378,000 compared with NOK 12,236,000 a year ago. Net loss was NOK 17,378,000 compared with NOK 12,236,000 a year ago. Net cash used in operations was NOK 17,407,000 against NOK 13,457,000 a year ago. Basic and diluted loss per share was NOK 2.25 against NOK 1.60 for the same period in the last year.

PCI Biotech Announces Completion of Second Group in Intra-Tumour Light Dose Escalation Part of the ENHANCE Study

PCI Biotech reported that the treatment evaluation of the second group in the intra-tumour light dose escalation part of the ENHANCE study has been completed. ENHANCE is a phase II study of Amphinex- in combination with the cytotoxic agent bleomycin in recurrent head and neck cancer patients. No serious safety concerns were raised and strong clinical effects with clear indications of tumour response were seen at this light dose level. A Dose Review Committee (DRC) of clinical experts and company representatives has been established to evaluate the results and provide recommendation for the continuation of the study. The DRC has recommended that three further patients are included at the same light dose level, before final selection of the light dose for proof of concept with intra-tumour treatment. Patients for the next group are currently being screened and will be treated with Amphinex- as soon as possible.

PCI Biotech Holding ASA Presents at BIO International Convention, Jun-25-2014 10:30 AM

PCI Biotech Holding ASA Presents at BIO International Convention, Jun-25-2014 10:30 AM. Venue: San Diego Convention Center, San Diego, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCIB:NO 23.90 NOK 0.00

PCIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PCIB.
View Industry Companies
 

Industry Analysis

PCIB

Industry Average

Valuation PCIB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.1x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PCI BIOTECH HOLDING ASA, please visit www.pcibiotech.no. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.